Skip to main content
. 2021 Mar 22;181(5):698–699. doi: 10.1001/jamainternmed.2020.7372

Table 2. Prevalence and Spending Effect of Shifting Nonaged Medicare Beneficiaries With ESKD to the Individual Market, 2016.

Percentage of nonaged Medicare beneficiaries with ESKD receiving dialysis shifting from traditional Medicare to individual market %
Individual market ESKD prevalence Change in average individual market claims spending
0 (Status quo) 0.10 NA
10 0.24 +4.1
20 0.37 +8.2
40 0.63 +16.4

Abbreviations: ESKD, end-stage kidney disease; NA, not applicable.